Chemotherapy for resectable microsatellite instability-high gastric cancer?

No abstract is available for this paper.

• Publication year

  2020

• Venue

  The Lancet Oncology

• Publication date

  2020-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(20)30025-5PMID 32007194
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting the LINC01515/miR-325-3p/ERBB4 axis suppresses gastric cancer progression.

  2026cites this paper
• Rectal Angiosarcoma: A Case Report Highlighting Multidisciplinary Strategies for Rare Malignancies

  2025cites this paper
• Molecular Classification of Resected Primary Duodenal Adenocarcinoma

  2025cites this paper
• A 107 Gene Nanostring Assay Effectively Translates the Cancer Genome Atlas, and Tumour Microenvironment Gastric Cancer Molecular Classification to a Patient‐Derived Organoid Model

  2025cites this paper
• Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis

  2024cites this paper
• Predictors of early recurrence of oesophagogastric adenocarcinoma after neoadjuvant FLOT.

  2024cites this paper
• Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair

  2024cites this paper
• Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis

  2024cites this paper
• Individual Survival Distributions Generated by Multi-Task Logistic Regression Yield a New Perspective on Molecular and Clinical Prognostic Factors in Gastric Adenocarcinoma

  2024cites this paper
• DEAD-box helicase family proteins: emerging targets in digestive system cancers and advances in targeted drug development

  2024cites this paper
• WNT2–SOX4 positive feedback loop promotes chemoresistance and tumorigenesis by inducing stem-cell like properties in gastric cancer

  2023cites this paper
• Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action

  2023cites this paper
• Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients

  2023cites this paper
• Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection

  2023cites this paper
• Low KCNQ1 expression is associated with unfavorable outcome and metabolism of gastric cancer.

  2023cites this paper
• Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer.

  2023cites this paper
• Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes in gastric cancer

  2023cites this paper
• Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study

  2023cites this paper
• Long non-coding RNA CNALPTC1 promotes gastric cancer progression by regulating the miR-6788-5p/PAK1 pathway

  2022cites this paper
• LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway

  2022cites this paper
• Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials

  2022cites this paper
• Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2022cites this paper
• Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment.

  2022cites this paper
• Comprehensive analysis of treatment-related adverse events of immunotherapy in advanced gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.

  2022cites this paper
• PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

  2022cites this paper
• Progress of Gastric Cancer Surgery in the era of Precision Medicine

  2021cites this paper
• An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

  2021cites this paper
• Gastric cancer

  2021cites this paper
• Results of the observational prospective RealFLOT study

  2021cites this paper
• Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors

  2021cites this paper
• Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy

  2021cites this paper
• Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy

  2021cites this paper
• Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer

  2021cites this paper
• Gastric cancer

  2020cites this paper
• MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma

  2020cites this paper
• Biomarkers for Precision Treatment in Gastric Cancer

  2020cites this paper
• Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer

  2020cites this paper